Stock info McKesson | Filter  Basic-Info

McKesson

The head office of McKesson is situated in San Francisco. McKesson's core business is the pharmaceutical sector. John H. Hammergren leads the company as CEO. The CFO of the company is Jeffrey C. Campbell. The global pharmaceutical companies gained around 75 percent over the period 2006-2016. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.

The past year gave good returns for McKesson investors

The period between December 2015 and December 2016 was a bad period for the investors. The stock lost almost 27 percent. Over the period 2011-2016 the stock rose a massive 82,32 percent. McKesson's revenues between 2011 and 2015 were quite unstable and moved between 122,46 billion dollars and 190,88 billion dollars. During 2011 and 2015 McKesson's net results were very volatile and fluctuated between 1,4 billion dollars and 2,34 billion dollars.

The American company paid out dividends in the past 5 years. Over the past 5 years the stock delivered an average dividend return of 3,48 percent.

Healthy financed: not so much debt McKesson

At the end of 2015 the American company had a balance sheet of around 56,56 billion dollars. At the end of 2015 the total debt positon equaled 47,64 billion dollars. This is around 84,22 percent of the total balance sheet. At the end of 2016 the American company was traded with a price/earnings-ratio of around 20. So investors paid 20 times the company's 2015's EPS. We could say that based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

At the end of 2015 the pharmaceutical company's market capitalization (the number of shares times the market price) equaled around 43,82 billion dollars. At the end of 2015 the American company had around 225 million stocks listed.

All of McKesson's annual reports are stored here. More information about McKesson can be found it's website. .